CN Patent

CN119371353B — 泛kras抑制剂及其医药用途

Assigned to Shandong First Medical University and Shandong Academy of Medical Sciences · Expires 2025-03-25 · 1y expired

What this patent protects

本发明涉及药物化学领域，涉及泛KRAS抑制剂及其医药用途，具体涉及一类靶向KRAS及其突变体KRAS G12C 、KRAS G12D 的化合物及其医药用途。对KRAS及其突变体的亲和性药理试验结果表明，本发明所述化合物对KRAS野生型及其KRAS G12C 突变型、KRAS G12D 突变型的亲和性均优于先导化合物，其对KRAS野生型及其KRAS G12C 突变型、KRAS G12D 突变型靶点具有潜在的抑制作用。

USPTO Abstract

本发明涉及药物化学领域，涉及泛KRAS抑制剂及其医药用途，具体涉及一类靶向KRAS及其突变体KRAS G12C 、KRAS G12D 的化合物及其医药用途。对KRAS及其突变体的亲和性药理试验结果表明，本发明所述化合物对KRAS野生型及其KRAS G12C 突变型、KRAS G12D 突变型的亲和性均优于先导化合物，其对KRAS野生型及其KRAS G12C 突变型、KRAS G12D 突变型靶点具有潜在的抑制作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN119371353B
Jurisdiction
CN
Classification
—
Expires
2025-03-25
Drug substance claim
No
Drug product claim
No
Assignee
Shandong First Medical University and Shandong Academy of Medical Sciences
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.